Basilea Pharmaceutica Ltd. Logo
 

Oncology 2009

 
 
 

Research

International Conference on Molecular Targets and Cancer Therapeutics, November 2009, Boston, United States of America

  • C-229 / BAL27862: A novel anticancer agent that dissociates microtubules and creates a distinct cellular phenotype. Bachmann F, Burger K, Pohlmann J, Kellenberger L, Lane H.  
  • C-233 / BAL27862: A unique microtubule-targeted agent with a potential for the treatment of human brain tumors. Schmitt-Hoffmann A, Klauer D, Gebhardt K, Brendle A, Fullhardt P, Hargreaves P, Bucher C, Schl√§fle C, Spickermann J, Defoin R, Burger K, Vuong V, Pruschy M, Bachmann F, Lane H.
 
Info